

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 January 2022 (13.01.2022)



(10) International Publication Number
WO 2022/008519 A1

(51) International Patent Classification:

A61K 39/12 (2006.01) A61P 31/20 (2006.01)
A61K 39/395 (2006.01) C07K 16/28 (2006.01)

(21) International Application Number:

PCT/EP2021/068680

(22) International Filing Date:

06 July 2021 (06.07.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/EP2020/069146

07 July 2020 (07.07.2020)

EP

(71) Applicants: **BIONTECH SE** [DE/DE]; An der Goldgrube 12, 55131 Mainz (DE). **TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH** [DE/DE]; Freiligrathstrasse 12, 55131 Mainz (DE).

(72) Inventors: **SAHIN, Ugur**; c/o BioNTech SE, An der Goldgrube 12, 55131 Mainz (DE). **KREITER, Sebastian**; c/o TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH, Freiligrathstrasse 12, 55131 Mainz (DE). **DIKEN, Mustafa**; c/o TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH, Freiligrathstrasse 12, 55131 Mainz (DE). **VASCOTTO, Fulvia**; c/o TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH, Freiligrathstrasse 12, 55131 Mainz (DE). **SALOMON, Nadja**; c/o TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH, Freiligrathstrasse 12, 55131 Mainz (DE). **GRUNWITZ, Christian**; c/o BioNTech SE, An der Goldgrube 12, 55131 Mainz (DE).

(74) Agent: **SCHNAPPAUF, Georg**; Zwicker Schnappauf & Partner Patentanwälte PartG mbB, Hansastr. 32, 80686 München (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,

KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: THERAPEUTIC RNA FOR HPV-POSITIVE CANCER

(57) Abstract: This disclosure relates to the field of therapeutic RNA to treat HPV-positive cancer, in particular anogenital, cervical and penile cancers and cancer in the head and neck region such as cancer in the genital region and head and neck squamous cell carcinoma (HNSCC). Disclosed herein are compositions, uses, and methods for treatment of HPV-positive cancers. Administration of therapeutic RNAs to a patient having HPV-positive cancer disclosed herein can reduce tumor size, prolong time to progressive disease, and/or protect against metastasis and/or recurrence of the tumor and ultimately extend survival time.

WO 2022/008519 A1